Fig. 4: Interfering with E-selectin binding decreases clearance of relapse AML CLCs.
From: Leukemia circulation kinetics revealed through blood exchange method
a Overview of experiment. Recombinant E-selectin is added to the relapse donor mouse prior to blood exchange with healthy recipient. b Decay profiles of relapse CLCs with or without recombinant E-selectin (rEsel) treatment in healthy recipient mice. c, d CLCs from relapse mice treated with recombinant E-selectin showed increase in both equilibration time (c, two-tailed t test p = 0.021) and fraction remaining (d, two tailed t-test p = 0.010). For decay profiles (b), shaded regions are represented by mean±standard error, and lines represent the best fit decay curve. Each dot represents an independent donor-recipient mouse pair.
